Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 23.4%

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 13,700 shares, an increase of 23.4% from the November 30th total of 11,100 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily volume of 355,500 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Several brokerages have commented on GTBP. Roth Capital raised GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd. Roth Mkm initiated coverage on GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective on the stock.

GT Biopharma Stock Performance

GT Biopharma stock traded up $0.02 during midday trading on Tuesday, reaching $3.07. The stock had a trading volume of 26,115 shares, compared to its average volume of 447,342. GT Biopharma has a 12 month low of $1.72 and a 12 month high of $10.66. The company has a fifty day moving average price of $2.89 and a two-hundred day moving average price of $2.58.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.